Compass Therapeutics Inc. (CMPX) - Total Liabilities
Based on the latest financial reports, Compass Therapeutics Inc. (CMPX) has total liabilities worth $21.65 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CMPX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Compass Therapeutics Inc. - Total Liabilities Trend (2018–2024)
This chart illustrates how Compass Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Compass Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Compass Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Okea ASA
OL:OKEA
|
Norway | Nkr1.96 Billion |
|
Vox Royalty Corp.
TO:VOXR
|
Canada | CA$22.24 Million |
|
Eik fasteignafélag hf
IC:EIK
|
Iceland | Ikr109.70 Billion |
|
Smcp SAS
PA:SMCP
|
France | €978.00 Million |
|
Shih Her Technologies
TWO:3551
|
Taiwan | NT$1.18 Billion |
|
Shihlin Paper Corp
TW:1903
|
Taiwan | NT$5.03 Billion |
|
Stack Capital Group Inc
TO:STCK
|
Canada | CA$13.20 Million |
|
Jiang Su New Technology Co. Ltd.
SHE:301229
|
China | CN¥563.13 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Compass Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CMPX company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Compass Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Compass Therapeutics Inc. (2018–2024)
The table below shows the annual total liabilities of Compass Therapeutics Inc. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $15.17 Million | +81.97% |
| 2023-12-31 | $8.34 Million | -53.70% |
| 2022-12-31 | $18.01 Million | +31.64% |
| 2021-12-31 | $13.68 Million | +14.32% |
| 2020-12-31 | $11.97 Million | -91.97% |
| 2019-12-31 | $148.98 Million | -0.28% |
| 2018-12-31 | $149.40 Million | -- |
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways… Read more